Key Metrics
Recent changes
- Sep 24, 2026Sep 24, 2026Raised $75M Series C BioSpace
- Sep 24, 2026Sep 24, 2026First reported total funding: $223M BioSpace
- Sep 24, 2026Sep 24, 2026New investor: Eli Lilly and Company BioSpace
- Sep 24, 2026Sep 24, 2026New investor: Quadrille Capital BioSpace
- Sep 24, 2026Sep 24, 2026New investor: Catalio Capital Management BioSpace
Earlier changes (5)
- Sep 24, 2026Sep 24, 2026New investor: Premji Invest BioSpace
- Sep 24, 2026Sep 24, 2026New investor: Andreessen Horowitz BioSpace
- Sep 24, 2026Sep 24, 2026New investor: 8VC BioSpace
- Sep 24, 2026Sep 24, 2026New investor: DFJ Growth BioSpace
- Sep 24, 2026Sep 24, 2026BigHat Biosciences Raises $75M To Scale AI Antibody Design Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2026 | Series C | $75M | — | DFJ GrowthLeadPremji InvestLeadCatalio Capital Management8VCAndreessen HorowitzEli Lilly and CompanyQuadrille CapitalLG Technology VenturesSigmas GroupAmgen VenturesMerck Global Health Innovation Fund+5 more | BioSpace |
Investors
Latest Pulse
- Sep 25, 2026Where September's Venture Dollars Actually WentThis issue's three reported funding deals total roughly $625 million, while AI infrastructure, robotics and digital health keep pulling a disproportionate share of the month's largest checks.→
- Sep 24, 2026AI Agent Security Just Had A $1.15B WeekIsland, Cyera and BigHat Biosciences alone raised more than $1.1 billion this week to build the layer that governs what AI agents can access and do -- evidence the market has already priced in the exact failure mode this issue's lead story just demonstrated.→
- Sep 24, 2026BigHat Biosciences Raises $75M To Scale AI Antibody DesignBigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, taking total funding to $223 million as its AI-designed antibody-drug conjugate enters a Phase 1 trial for gastric cancer.→
Coverage Timeline
newest firstAll Coverage
FUNDING$1.125B across 4 rounds
AI Agent Security Just Had A $1.15B Week
Island, Cyera and BigHat Biosciences alone raised more than $1.1 billion this week to build the layer that governs what AI agents can access and do -- evidence the market has already priced in the exact failure mode this issue's lead story just demonstrated.
BY THE NUMBERS
BigHat Biosciences Raises $75M To Scale AI Antibody Design
FUNDING$75M Series C
BigHat Biosciences Raises $75M To Scale AI Antibody Design
BigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, taking total funding to $223 million as its AI-designed antibody-drug conjugate enters a Phase 1 trial for gastric cancer.
DEEP DIVE
Related Companies
BigHat Biosciences FAQ
How much has BigHat Biosciences raised?
BigHat Biosciences has raised $223M in total funding (As of Sep 24, 2026, BioSpace).
Who are BigHat Biosciences's investors?
BigHat Biosciences's investors include DFJ Growth, Premji Invest, 8VC, Andreessen Horowitz, Catalio Capital Management, and 2 more (As of Sep 24, 2026).
Sources & methodologyshow
Where these figures come from
- BioSpaceValue Add VC data2 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.